2024
His Serene Highness Prince Albert II of Monaco
2025 ROY VAGELOS PRO BONO HUMANUM AWARD
The Galien Foundation Presents Michael J. Fox with 2025 Roy Vagelos, Pro Bono Humanum Award for Global Health Equity

Stanley T. Crooke, MD, Ph.D., Founder, Chief Executive Officer and Chairman of the Board, n-Lorem foundation

Michael J. Fox
"The Galien Foundation is honored to recognize Michael J. Fox for his unwavering commitment to Parkinson's research and advocacy. Through his foundation, he has raised global awareness, driven major scientific advances—including a breakthrough biomarker and new treatments—and offered hope to patients worldwide. His candor and resolve have transformed public understanding of the disease, reducing stigma and inspiring engagement in medical progress," said Kenneth C. Frazier, Co-Chair of Prix Galien USA Committees.
"Michael J. Fox has changed the way the world sees both Parkinson's disease and the power of science to address it. Through his vision and leadership, The Michael J. Fox Foundation has become a model for how advocacy and research can work hand in hand to deliver real progress. The Galien Foundation is privileged to celebrate not only the advances his foundation has achieved, but also the hope, dignity, and inspiration he continues to give to patients, families, and scientists everywhere," said Michael Rosenblatt, MD, Co-Chair of Prix Galien USA Committees, Former Dean of Tufts University School of Medicine, and former Chief Medical Officer of Merck & Co. Inc.
Driven by his personal experience with Parkinson's disease, Michael J. Fox established The Michael J. Fox Foundation to accelerate scientific research, advance the development of novel therapies, and improve outcomes for individuals affected by the condition. Under his guidance, the Foundation has become a global leader in funding innovative studies, supporting clinical trials, and fostering collaboration across the scientific and medical communities. His sustained commitment continues to propel progress in the field, and those seeking to support

The Galien Foundation’s Prix Galien, Roy Vagelos, Pro Bono Humanum Award is in honor of Dr. P. Roy Vagelos, Retired Chairman and CEO, Merck & Co., Inc. Chairman of the Board, Regeneron Pharmaceuticals. Dr. Vagelos, who chaired the Prix Galien USA Awards Committee from its inception until December 2017, was also the first recipient of the Pro Bono Humanum Award, established in 2007 under the sponsorship of the late Foundation Honorary President and 1986 Nobel Peace Prize recipient, Pr. Elie Wiesel.
The annual Prix Galien, Roy Vagelos, Pro Bono Humanum Award recognizes an individual’s outstanding efforts to improving the human condition through the application of pharmaceutical science to problems of developing or underserved populations worldwide.

P. Roy Vagelos
Prix Galien USA Committee Chair 2012-2017
Past Pro Bono Humanum Award Winners:
2023
Mae. C. Jemison
In recognition of your exceptional scientific achievements, medical advocacy, and humanitarian efforts, our committee of distinguished scientists and Nobel laureates acknowledges your outstanding contributions. As a physician, engineer, and former NASA astronaut, you've excelled in medicine and space science, conducting groundbreaking research aboard the Space Shuttle Endeavour in 1992 that advanced our understanding of human physiology in space.
Your tireless efforts in promoting diversity in STEM fields, inspiring underrepresented communities, and mentoring young students have been truly commendable. Your dedication to science education and healthcare access has empowered future generations in science and medicine.
Furthermore, your humanitarian work, including serving as a Peace Corps medical officer in West Africa and improving healthcare infrastructure in underserved areas, demonstrates your commitment to addressing global health issues through science and medicine.
Your contributions to science, medicine, and humanitarian efforts have left an indelible mark on society, inspiring us all.
2022
Stanley T. Crooke
In recognition of his nearly 50 years of dedication to a novel, clinically endorsed concept of using synthetic oligonucleotides to control the expression of genes and proteins that impact disease. His singular dedication to this RNA-driven antisense platform provided a new, highly personalized pathway to resolving some of the most difficult biomedical challenges, with the ultimate potential of treating multiple infections, inflammatory conditions and cancers targeted to individual patient profiles and with minimal side-effects. Due to Dr. Crooke’s years of effort as a researcher, corporate R&D executive, biotech innovator and philanthropist, nearly a dozen antisense oligonucleotides (ASO) have been approved for clinical use since 1998; additional clinical trials focused in high unmet medical need areas like neuroscience are underway. Dr. Crooke is also recognized for his leadership in being among the first in industry to make a commitment to open science a key element of the modern R&D enterprise and to embrace the principle that even patients with the rarest of afflictions deserve the best talent and expertise our R&D industry can offer. Untold thousands of patients formerly with no hope of a cure stand to benefit from his belief in the promise of this entirely new class of medicines.
2021
(l-r) Stephane Bancel; Albert Bourla; Alex Gorsky; David Ricks; Pascal Soriot; George D. Yancopoulos
In recognition of the monumental feat of having developed, in less than a year, vaccines against COVID-19, as well as having developed several novel antiviral drugs that treat COVID-19 symptoms based on innovative monoclonal antibody platforms. The six companies together responded to the pandemic in record time, with safe, effective treatments that hold the promise of reducing mortality and restoring normal life for untold millions of vulnerable patients.
2019
Jim and Marilyn Simons
The Simons Foundation In recognition of their proactive support of basic scientific research undertaken in the pursuit of understanding the phenomena of our world, often including research by scientists in the early stages of their careers, a new collaborative funding model to facilitate cross-disciplinary breakthroughs, and efforts to inspire emerging and current philanthropists to dedicate a portion of their philanthropy to basic science.
2018
Bill and Melinda Gates
Bill & Melinda Gates Foundation
In recognition of their extraordinary work championing scientific and technological innovation to improve life for the world’s poorest people. As co-chairs of the Bill & Melinda Gates Foundation, they have catalyzed unprecedented progress in global health, poverty reduction, and public education in the U.S.
2017
Jimmy Carter
Former U.S. President &
Co-Founder, The Carter Center
For playing a leadership role in the elimination of river blindness in four of the six Latin American countries where it was endemic and halting the disease’s transmission in several locations in Africa where more than 99 percent of the global cases exist.
2016
Paula S. Apsell
Executive Producer, PBS NOVA series & Director, Science Unit, WGBH
For turning great science into a human story, showing that scientific literacy is society’s first line of defense against the destructive forces of fear and ignorance that challenge further progress in human health.
2015
Pr. Mary-Claire King
Professor, Genome Sciences and Medical Genetics, University of Washington
In recognition of her work in transforming the application of human genetics to medicine through identification of the first gene, BRCA1, responsible for inherited susceptibility to breast cancer. And for pioneering the application of genetic sequencing in forensics to identify victims of human rights abuse.
2014
Dr. Bernard Kouchner
Co-Founder, Doctors Without Border & Former French Minister of Foreign and European Affairs
In recognition of his role in the creation, from amongst French doctors, this group of “Doctors Without Borders” who have lent the modern field of humanitarian medicine both legitimacy and worldwide acclaim and for his fieldwork that has nurtured and developed, not only among public opinion but also within various governments, the notion of the universality of humanitarian action and the concept of the Non-Governmental Organization.
2010
Bill Clinton and Philippe Douste-Blazy
Founder, Clinton Foundation and Former U.S. President; Chairman, UNITAID In recognition of their achievements in providing treatment and increasing access to medicines for underserved populations through the UNITAID and Clinton Foundation HIV/AIDS Initiative (CHAI) partnership.
2009
Barry Bloom and Jeffrey Sachs
Professor of Public Health, Harvard University; Director, Earth Institute, Columbia University Harvard Professor Barry Bloom for bringing the fruits of basic biological science to those who are most needy. Columbia University Earth Institute Director Jeffrey Sachs for bringing the fruits of scholarly economics to bear our problems that have plagued the world for millennia.
2007
P. Roy Vagelos
Retired Chairman and CEO, Merck & Co., Inc.; Chairman of the Board Regeneron Pharmaceuticals, Inc.
For the River Blindness Program and his historic decision to donate the drug Mectizan to more than 530 million people in 34 countries to treat and prevent river blindness “as much as necessary for as long as necessary.”